Union européenne - islandais - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - blæðandi hiti, ebóla - bóluefni - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Union européenne - islandais - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - blæðandi hiti, ebóla - bóluefni - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Union européenne - islandais - EMA (European Medicines Agency)

dynavax gmbh - lifrarbólga b yfirborðs mótefnavaka - lifrarbólga b - bóluefni - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Union européenne - islandais - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - Ónæmislyf fyrir canidae - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Union européenne - islandais - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - Ónæmiskerfið sera og mótefni, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Union européenne - islandais - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - bóluefni - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - tbe antigen virus - stungulyf, dreifa - 0,5 ml

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - tbe antigen virus - stungulyf, dreifa - 0,25 ml

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

merck sharp & dohme b.v.* - varicella virus oka/merck strain, (live, attenuated) produced in human diploid (mrc-5) cells - stungulyfsstofn og leysir, dreifa

Union européenne - islandais - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - bóluefni - hexyon (dtap-ipv-hb-hib) er ætlað fyrir aðal og orku bólusetningu ungbarna og smábörn frá sex vikna gegn barnaveiki, stífkrampa, stífkrampa, lifrarbólgu b, mænusótt og innrásar sjúkdóma sem orsakast af haemophilus influenzae gerð b (hib). notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.